Chemistry:AOP-208

From HandWiki

AOP-208, also known as LB-208, is a selective serotonin 5-HT1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes.[1][2][3] It is taken orally.[1][3] The drug is being developed by AOP Orphan Pharmaceuticals AG and Leukos Biotech.[1][2] As of October 2024, it is in phase 1 clinical trials for lymphoma and solid tumors and is in the preclinical research stage of development for acute myeloid leukemia and myelodysplastic syndromes.[1][2] The chemical structure of AOP-208 does not yet appear to have been disclosed.[1]

References